|
Orthologous residues
|
|
XBP1 (human): S68‑p, XBP1 iso2 (human): S68‑p, XBP1 (mouse): S61‑p, XBP1 iso2 (mouse): S61‑p, XBP1 (rat): S61‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mass spectrometry, mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), adipose tissue, liver, MEF (fibroblast), muscle
|
|
Cellular systems studied:
cell lines, tissue
|
|
Species studied:
human, mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
p38-alpha (mouse)
|
activation of upstream enzyme, pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
anisomycin
|
|
|
|
increase
|
|
|
fasting
|
|
|
|
decrease
|
in lean (wt) mice
|
|
refeeding
|
|
|
|
increase
|
in lean (wt ) mice
|
|
SB203580
|
refeeding
|
|
|
inhibit treatment-induced increase
|
in lean (wt) mice
|
|
refeeding
|
|
|
|
decrease
|
in obese (ob/ob) mice
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization
|
|
Comments:
important for nuclear translocation of XBP1- not in obese (ob/ob) mice
|